<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186835</url>
  </required_header>
  <id_info>
    <org_study_id>MA-stu24810</org_study_id>
    <nct_id>NCT01186835</nct_id>
  </id_info>
  <brief_title>Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone</brief_title>
  <official_title>Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone: A Split-face, Rater-blinded Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether the use of botulinum toxin (Dysport ®) in&#xD;
      conjunction with a hyaluronic acid filler (Restylane®) will improve the appearance of&#xD;
      wrinkles on the forehead and glabella (area between the eyebrows) better than botulinum toxin&#xD;
      alone. These two products have been FDA approved to improve the appearance of facial&#xD;
      wrinkles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure:</measure>
    <time_frame>1 year</time_frame>
    <description>Two blinded dermatologists will rate each photograph of each subject at baseline, week 2, month 3, and month 6. The raters will provide a glabellar wrinkle score and a forehead wrinkle score for each photograph. The raters will not know what treatments the subjects received or at what point in time the photographs were taken.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure: Percent Improvement</measure>
    <time_frame>1 year</time_frame>
    <description>Two blinded dermatologists will also rate the percent improvement between the before and after photographs (Appendix III).&#xD;
A live blinded dermatologist will determine which side looks better at week 0, week 2, month 3, and month 6.&#xD;
A subject self-evaluation will be administered at week 2, month 3, and month 6.&#xD;
A subject satisfaction questionnaire will be administered at month 6.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Forehead/Glabellar Rhytid Complexes</condition>
  <arm_group>
    <arm_group_label>Combination Botulinum Toxin A and Hyaluronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One side of face treated with the combination of Botulinum Toxin A and Hyaluronic Acid injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin A alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Other side of face treated with =Botulinum Toxin A injection alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combination Botulinum Toxin A and Hyaluronic Acid</intervention_name>
    <description>One side of subject's face will randomly be assigned combination treatment.</description>
    <arm_group_label>Combination Botulinum Toxin A and Hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Botulinum Toxin A</intervention_name>
    <description>Other side of subjects face with receive Botulinum Toxin A treatment alone.</description>
    <arm_group_label>Botulinum Toxin A alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In good health&#xD;
&#xD;
          -  Is 18-65 years of age&#xD;
&#xD;
          -  Has static and dynamic forehead/glabellar wrinkles&#xD;
&#xD;
          -  Has willingness and the ability to understand and provide informed consent and&#xD;
             communicate with the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Has received the following treatments in the forehead or glabellar region:&#xD;
&#xD;
               -  botulinum toxin injections in the past 6 months&#xD;
&#xD;
               -  ablative laser procedure in the past 6 months&#xD;
&#xD;
               -  radiofrequency device treatment in the past 6 months&#xD;
&#xD;
               -  ultrasound device treatment in the past 6 months&#xD;
&#xD;
               -  medium to deep chemical peel in the past 6 months&#xD;
&#xD;
               -  temporary soft tissue augmentation material in the past year&#xD;
&#xD;
               -  semi-permanent soft tissue augmentation material in the past 2 years&#xD;
&#xD;
               -  permanent soft tissue augmentation material&#xD;
&#xD;
          -  Is planning to receive within the next 6 months, any cosmetic procedure (such as any&#xD;
             chemical peels, botulinum toxin injections, ablative or non-ablative laser procedures,&#xD;
             filler injections, radiofrequency procedures, dermabrasion, ultrasound and face&#xD;
             lifting procedures) in the forehead or glabellar region.&#xD;
&#xD;
          -  Is planning to use tretinoin or retinoic acid in the next 6 months&#xD;
&#xD;
          -  Has an active infection in the forehead or glabellar region (excluding mild acne)&#xD;
&#xD;
          -  Is allergic to cow's-milk protein&#xD;
&#xD;
          -  Is allergic to albumin&#xD;
&#xD;
          -  Taking aminoglycoside&#xD;
&#xD;
          -  Has prior history of nodule formation or hypersensitivity reactions to lidocaine or&#xD;
             hyaluronic acid derivatives&#xD;
&#xD;
          -  Is currently using anticoagulation therapy&#xD;
&#xD;
          -  Has a history of bleeding disorders&#xD;
&#xD;
          -  Is unable to understand the protocol or to give informed consent&#xD;
&#xD;
          -  Has a mental illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murad Alam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Murad Alam</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

